SEC Comment Letter for Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259) (OTLC) — Nov 25, 2019
Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259)
Date: Nov. 25, 2019 · CIK: 0000908259 · Accession: 0000000000-19-015817
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-21990
Letter
November 22, 2019 Vuong Trieu, Ph.D. Chief Executive Officer Mateon Therapeutics, Inc. 23937 Agoura Road, Suite 107 Agoura Hills, CA 91301 Re:Mateon Therapeutics, Inc. Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A Filed November 18, 2019 File No. 000-21990 Dear Dr. Trieu: We have reviewed your filing and have the following comment. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to these comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to the comment, we may have additional comments. Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A filed November 18, 2019 Corporate Action No. 4: Approval of Recapitalization, page 13 1.We note your revisions in response to our prior comment 7. To the extent the Financing Transaction condition contained in the PointR Data merger agreement is still applicable, please disclose this condition where appropriate in your proxy statement. With reference to Item 11(c) and (d) of Schedule 14A, please also expand your disclosure concerning Corporate Action No. 4 to discuss the effects of the recapitalization and potential issuances of newly authorized common stock. In this regard, please quantify the number common shares presently outstanding as compared to the number of common shares outstanding following the proposed recapitalization. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameVuong Trieu, Ph.D. Comapany NameMateon Therapeutics, Inc. November 22, 2019 Page 2 FirstName LastName Vuong Trieu, Ph.D. Mateon Therapeutics, Inc. November 22, 2019 Page 2 You may contact Irene Paik at (202) 551-6553 or Joseph McCann at (202) 551-6262 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: James A. Mercer III, Esq.
Show Raw Text
November 22, 2019
Vuong Trieu, Ph.D.
Chief Executive Officer
Mateon Therapeutics, Inc.
23937 Agoura Road, Suite 107
Agoura Hills, CA 91301
Re:Mateon Therapeutics, Inc.
Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A
Filed November 18, 2019
File No. 000-21990
Dear Dr. Trieu:
We have reviewed your filing and have the following comment. In some of our
comments, we may ask you to provide us with information so we may better understand your
disclosure.
Please respond to these comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to the comment, we may have additional comments.
Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A filed November 18, 2019
Corporate Action No. 4: Approval of Recapitalization, page 13
1.We note your revisions in response to our prior comment 7. To the extent the Financing
Transaction condition contained in the PointR Data merger agreement is still applicable,
please disclose this condition where appropriate in your proxy statement. With reference
to Item 11(c) and (d) of Schedule 14A, please also expand your disclosure concerning
Corporate Action No. 4 to discuss the effects of the recapitalization and potential
issuances of newly authorized common stock. In this regard, please quantify the number
common shares presently outstanding as compared to the number of common
shares outstanding following the proposed recapitalization.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
FirstName LastNameVuong Trieu, Ph.D.
Comapany NameMateon Therapeutics, Inc.
November 22, 2019 Page 2
FirstName LastName
Vuong Trieu, Ph.D.
Mateon Therapeutics, Inc.
November 22, 2019
Page 2
You may contact Irene Paik at (202) 551-6553 or Joseph McCann at (202) 551-6262 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: James A. Mercer III, Esq.